MR弹性成像硬度预测肝细胞癌对TACE难治性的价值
本研究回顾性纳入112例在初次TACE前1个月内接受MRI与三维MRE的肝细胞癌患者,按mRECIST与AASLD标准判断TACE难治性。结果显示肿瘤大小、BCLC分期与肿瘤硬度为独立预测因素,联合列线图模型预测TACE难治性的AUC为0.853。
要点
- 三维MRE肿瘤硬度可作为预测HCC患者TACE难治性的补充影像标志物。
- 联合肿瘤硬度、肿瘤大小与BCLC分期的列线图模型预测效能最高。
- 列线图判定为TACE难治的患者无进展生存期显著缩短。
核心结论
- 三维MRE获得的肿瘤硬度可作为预测肝细胞癌患者发生TACE难治性的补充生物标志物。
研究设计与样本
- 回顾性研究,纳入2017至2024年间112例在初次TACE前1个月内接受MRI和三维MRE检查的肝细胞癌患者。
- 参考标准为基于改良实体瘤疗效评价标准(mRECIST)的治疗反应评估及AASLD指南定义的TACE难治性。
- 采用logistic回归与受试者工作特征曲线下面积(AUC)分析,并以1000次bootstrap重抽样验证模型。
关键影像表现/征象
- 肿瘤大小、BCLC分期和肿瘤硬度(TS)为TACE难治性的独立预测因素。
- 临床-影像学-MRE联合列线图模型预测TACE难治性的AUC为0.853。
- 包含形态学模式、BCLC分期和不完整包膜的临床-影像学模型AUC为0.785,联合模型优于该模型(p=0.044)。
诊断标准与关键数值
- 在112例患者中,63例(56.3%)符合TACE难治性标准。
- 多因素分析显示肿瘤大小、BCLC分期与肿瘤硬度均为TACE难治性的独立预测因素(均p<0.05)。
- bootstrap验证后,联合列线图模型预测TACE难治性的AUC为0.853。
临床应用与阅片要点
- 对拟行初次TACE的HCC患者,可在术前MRI检查中加入三维MRE,利用肿瘤硬度辅助评估TACE难治风险。
- 报告时可记录肿瘤硬度、肿瘤大小、BCLC分期与包膜完整性,以支持TACE疗效预判。
- 被列线图判定为TACE难治的患者无进展生存期显著缩短(p<0.05),应密切随访或考虑调整治疗策略。
局限性
- 本研究为回顾性设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This study aimed to evaluate the value of MRE-based stiffness for preoperatively predicting HCC refractory to TACE.
METHODS: This retrospective study included 112 patients with HCC who underwent MRI and three-dimensional (3D) MRE within one month before initial TACE from 2017 to 2024. Imaging features, clinical information and stiffness values were analyzed to develop the clinical-radiological and nomogram models. Two radiologists reviewed the images and treatment response according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST). TACE refractoriness was determined in patients after 1-2 TACE sessions based on AASLD guidelines. Logistic regression and area under the receiver operating characteristic curve (AUC) analyses were used to identify predictors of TACE refractoriness and evaluate model performances. The final models were validated by 1000 bootstrap resamples. Kaplan-Meier analysis was used to assess progression-free survival (PFS).
RESULTS: Among 112 patients, 63 (56.3 %) met the criteria for TACE refractoriness. Multivariable analysis showed that tumor size, BCLC stage and tumor stiffness (TS) were independent predictors of TACE refractoriness (all p < 0.05) in the clinical-radiological-MRE nomogram model. After bootstrap validation, the combined nomogram model showed the highest predictive performance (AUC = 0.853) for predicting TACE refractoriness, outperformed the clinical-radiological model integrating morphological pattern, BCLC stage and incomplete capsule (AUC = 0.785, p = 0.044). Patients classified as TACE-refractory by the nomogram had significantly shorter PFS than those classified as TACE-responsive (p < 0.05).
CONCLUSION: 3D MRE-based TS may serve as a complementary biomarker for predicting TACE refractoriness in HCC patients.
引用
- Wang, Ouyang, Zhou, et al. MR Elastography-based stiffness as a marker for predicting hepatocellular carcinoma refractory to transarterial chemoembolization. Eur J Radiol. 2026. PMID: 42753335. doi:10.1016/j.ejrad.2026.113240
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。